VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Technical Scanner
RSI, Moving averages & volume momentum signals
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
Minervini — VCPContraction bases in Stage 2 uptrends
Minervini — Trend TemplateFull 8-rule Stage 2 screen
O'Neil — Cup with HandleBase breakouts with RS leadership
O'Neil — CANSLIM LeadersGrowth leaders with RS ≥ 85
Qullamaggie — High Tight FlagsPower plays after a large advance
Qullamaggie — Momentum Leaders1/3/6-month strength leaders
Livermore — Pivotal PointsMulti-touch resistance breakouts
View All Playbooks...
Breakouts
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
Breakouts
WatchlistPricing
Ctrl K
Pricing
ACHC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
ACHCAcadia Healthcare Company, Inc.
$28.51$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. ACHC
  4. Financial Ratios

Acadia Healthcare Company, Inc. (ACHC) Financial Ratios

Latest Ratios: P/E Ratio -2.3x · EV/EBITDA 9.0x · ROE -41.4%. (2011–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

ACHC Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$2.7B$1.3B$3.7B$7.1B$7.5B$5.5B$4.5B$2.9B$2.2B$2.8B$2.8B
Enterprise Value$5.2B$3.8B$5.7B$8.5B$9.0B$7.0B$7.3B$6.1B$5.4B$6.0B$6.1B
P/E Ratio →-2.34—14.26—27.6228.90—26.79—14.19472.86
P/S Ratio0.800.391.162.412.892.382.131.450.741.001.01
P/B Ratio1.210.601.142.452.602.132.341.160.951.091.30
P/FCF———185.1089.2842.5010.0760.5030.9022.6552.69
P/OCF20.129.7628.1415.3019.8014.726.768.765.427.117.87

P/E links to full P/E history page with 30-year chart

ACHC EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.151.792.903.443.033.513.021.792.122.16
EV / EBITDA8.976.608.4213.2815.3213.4616.778.109.4310.3510.47
EV / EBIT13.34—12.35149.4420.2019.8921.4419.3421.3813.7313.65
EV / FCF———222.02106.2454.1116.58125.9774.1847.95112.51

ACHC Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin17.6%17.6%22.6%23.3%96.2%96.1%95.8%40.6%41.0%41.8%41.0%
Operating Margin11.7%11.7%16.6%17.3%17.9%17.9%—32.9%13.7%15.4%15.8%
Net Profit Margin-33.3%-33.3%8.1%-0.7%10.5%8.2%-32.2%5.4%-5.8%7.0%0.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-41.4%-41.4%8.4%-0.7%10.0%8.5%-30.5%4.5%-7.1%8.4%0.3%
ROA-19.2%-19.2%4.5%-0.4%5.6%3.4%-10.0%1.7%-2.8%3.2%0.1%
ROIC5.9%5.9%8.2%8.8%8.3%7.0%—8.9%5.5%5.9%7.1%
ROCE7.5%7.5%10.6%11.2%10.4%8.7%—10.9%7.0%7.5%9.2%

ACHC Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity1.241.240.650.520.530.631.711.301.351.251.50
Debt / EBITDA4.604.603.102.362.613.147.454.355.595.585.67
Net Debt / Equity—1.180.630.490.490.581.521.261.331.221.48
Net Debt / EBITDA4.374.372.992.212.452.896.594.215.505.465.57
Debt / FCF———36.9216.9611.606.5165.4743.2825.3059.82
Interest Coverage-6.68-6.683.940.696.364.582.161.681.362.492.45

ACHC Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio1.551.551.000.671.301.221.931.171.081.251.25
Quick Ratio1.541.540.990.671.291.211.931.161.071.241.23
Cash Ratio0.250.250.130.110.250.330.290.210.120.180.17
Asset Turnover—0.600.530.550.520.490.320.290.490.440.47
Inventory Turnover480.01480.01431.90423.8019.7018.9517.98292.73351.86344.81358.14
Days Sales Outstanding—60.0748.8353.5349.4648.0151.8858.3538.5444.3940.87

ACHC Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield——7.0%—3.6%3.5%—3.7%—7.0%0.2%
FCF Yield———0.5%1.1%2.4%9.9%1.7%3.2%4.4%1.9%
Buyback Yield1.9%3.9%0.2%0.7%0.0%0.1%0.0%0.1%0.2%0.1%0.0%
Total Shareholder Yield1.9%3.9%0.2%0.7%0.0%0.1%0.0%0.1%0.2%0.1%0.0%
Shares Outstanding—$91M$92M$91M$92M$91M$89M$88M$87M$87M$86M

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Labor shortages and litigation

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Margin Volatility Masks Core Pressures

Gross margin swung from 96.7% in Q2 2025 to 16.6% in Q2 2026, reflecting cost reclassification; operating margin fell to 10.1%, indicating labor inflation and fixed reimbursement caps, as per quarterly filings.

The dramatic gross margin swing is largely a classification artifact, but the underlying trend is clear: operating margin has compressed from 17.9% in Q2 2024 to 10.1% in Q2 2026, even as revenue remained flat. This suggests that labor costs and other operating expenses are consuming a larger share of each dollar of revenue, consistent with the industry-wide nursing shortage and mandatory staffing ratios. The TTM net margin of -33.3% is heavily distorted by a massive non-recurring charge in Q4 2025, likely a legal settlement or impairment, which masks the underlying operational profitability that appears to be in the low-to-mid single digits on a net basis.

Return on Capital Decays Sharply

ROIC fell from 2.2% in Q2 2024 to 1.4% in Q2 2026, while ROE dropped from 2.6% to 0.5%, indicating that capital deployed is generating diminishing returns, as reported in financial statements.

The decline in ROIC and ROE is not just a function of the one-time loss; even excluding Q4 2025, the trend is downward. In Q2 2024, ROIC was 2.2%, and by Q2 2026 it had fallen to 1.4%, despite a growing asset base. This suggests that new investments, particularly in JV facilities, are not yet generating returns commensurate with their cost, or that existing assets are becoming less productive due to staffing constraints. The company's heavy investment in PPE (up to $3.2B) without corresponding revenue growth implies that capacity is not being fully utilized, likely because unstaffed beds generate no revenue.

Working Capital Efficiency Distorted by Payables

CCC swung from -608 days in Q2 2025 to +41 days in Q2 2026, driven by a collapse in DPO from 676 to 17 days, indicating a normalization of payment terms, based on reported figures.

The extreme negative CCC in 2024 and early 2025 was an artifact of unusually high DPO, which likely reflected delayed payments or accounting anomalies. The recent normalization to a positive CCC of 41 days is more typical for a healthcare provider, but it also means that Acadia can no longer rely on supplier financing to fund its operations. DSO has remained stable around 53-59 days, suggesting consistent billing and collection practices. The sharp reduction in DPO may indicate a shift in vendor relationships or a need to pay more promptly to secure scarce clinical supplies and labor, which could pressure cash flow.

Leverage Climbs as Debt Service Tightens

D/E rose from 0.64 in Q2 2024 to 1.17 in Q2 2026, while interest coverage fell from 4.65x to 3.30x, indicating reduced financial flexibility, as per recent balance sheet data.

The increase in leverage is partly due to the erosion of equity from the Q4 2025 loss, but total debt also grew from $2.0B to $2.6B over the same period. Interest coverage of 3.3x is still adequate but has deteriorated from 4.65x, and the D/EBITDA ratio of 18.55x is extremely high, though this is distorted by the depressed EBITDA from the one-time charge. Excluding that charge, D/EBITDA would be closer to 5-6x, which is more manageable. However, the trend is concerning: the company is taking on more debt while its earnings power is weakening, which could strain debt service if interest rates remain elevated.

Liquidity Improves but Cash Buffer Thin

Current ratio improved to 1.57 in Q2 2026 from 1.18 in Q2 2024, yet cash of $171M covers only 8% of total debt, indicating a modest liquidity cushion, as reported in financial statements.

The current ratio is healthy, and the quick ratio of 1.56 suggests that inventory is not a significant liquidity concern, which is typical for a service business. However, the absolute cash balance is small relative to the debt load, and the company's reliance on operating cash flow to service debt is evident. In Q2 2026, operating cash flow of $162.1M was strong, but it is volatile, as seen in the negative FCF margins in prior quarters. Under a severe stress scenario—such as a prolonged labor shortage or a large legal settlement—the liquidity position could deteriorate quickly, given the thin cash buffer.

EV/EBITDA Misleads on Earnings Quality

The most misapplied ratio is EV/EBITDA, which at 9.15x appears cheap, but the EBITDA is distorted by one-time charges and labor cost inflation, obscuring true earning power, as per recent filings.

Investors often use EV/EBITDA to value healthcare facilities, but for Acadia, this ratio is currently misleading. The TTM EBITDA is depressed by the massive Q4 2025 charge, making the multiple appear artificially low. Conversely, the forward EV/EBITDA of 17.18x suggests that the market expects a recovery, but this may be overly optimistic if labor costs remain elevated. A better metric is EV/EBITDAR (earnings before interest, taxes, depreciation, amortization, and rent), which normalizes for the high fixed costs of facility leases and labor. Alternatively, analysts should focus on cash flow-based metrics like EV/OCF, which better captures the company's ability to generate cash from operations, as evidenced by the divergence between cumulative OCF of $385.5M and cumulative net income of -$924.7M over the past ten quarters.

Download Financial Ratios Data

Includes 30+ ratios · 15 years · Updated daily

Consensus & Technical Research Suite
Open ACHC Terminal

ACHC Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ACHC — Frequently Asked Questions

Quick answers to the most common questions about buying ACHC stock.

What is Acadia Healthcare Company, Inc.'s P/E ratio?

Acadia Healthcare Company, Inc.'s current P/E ratio is -2.3x. The historical average is 32.0x.

What is Acadia Healthcare Company, Inc.'s EV/EBITDA?

Acadia Healthcare Company, Inc.'s current EV/EBITDA is 9.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.5x.

What is Acadia Healthcare Company, Inc.'s ROE?

Acadia Healthcare Company, Inc.'s return on equity (ROE) is -41.4%. The historical average is -2.5%.

Is ACHC stock overvalued?

Based on historical data, Acadia Healthcare Company, Inc. is trading at a P/E of -2.3x. Compare with industry peers and growth rates for a complete picture.

What are Acadia Healthcare Company, Inc.'s profit margins?

Acadia Healthcare Company, Inc. has 17.6% gross margin and 11.7% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does Acadia Healthcare Company, Inc. have?

Acadia Healthcare Company, Inc.'s Debt/EBITDA ratio is 4.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.